Moneycontrol
Get App
you are here: HomeNewsBusiness
Last Updated : Feb 26, 2020 12:01 PM IST | Source: PTI

Aurobindo Pharma gets EIR with VAI status from USFDA for Hyderabad facility

According to the US health regulator, a VAI classification "means objectionable conditions or practices were found but the agency is not prepared to take or recommend any administrative or regulatory action".

Representative Image
Representative Image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Aurobindo Pharma Ltd on February 26, said that it has received an establishment inspection report from the US health regulator with Voluntary Action Initiated (VAl) status for its Unit VIII manufacturing facility in Hyderabad.

"Further to our intimation dated November 6, 2019 with regard to the USFDA inspection of Unit VIII, API manufacturing facility at Gaddapotharam, Hyderabad, we would like to inform that the company has received the Establishment Inspection Report (EIR) with VAl status from the USFDA," the drug firm said in a filing to BSE.

According to the US health regulator, a VAI classification "means objectionable conditions or practices were found but the agency is not prepared to take or recommend any administrative or regulatory action".

Close

USFDA issues an EIR to the company when an inspection is satisfactorily closed.

Shares of Aurobindo Pharma were trading at Rs 508.50 a piece on BSE, up 0.87 percent from the previous close.

Time to show-off your poker skills and win Rs.25 lakhs with no investment. Register Now!

First Published on Feb 26, 2020 11:47 am
Sections
Follow us on